Patient-derived monoclonal anti-HPA-1a can induce platelet activation through FcγRIIa
Oosterhoff, J. J., van Brummelen, S. R., Giulini, M., De Cuyper, I. M., Visser, R., Kapur, R., Gstoettner, C., DominguezV ega, E., et al.
immunology
Quick verdict
Claims M-204 anti-HPA-1a mAb aggregates platelets via bivalent binding and FcγRIIa; convincing fragment controls but n=2–3 donors and indirect mechanism.
Summary
This bioRxiv preprint characterizes two patient-derived monoclonal anti-HPA-1a antibodies, D-204 and M-204, isolated from a mother with severe fetal and neonatal alloimmune thrombocytopenia (FNAIT). SDS-PAGE and nanoLC-MS show M-204 alone carries an N-linked Fab glycan, confirmed by an N72D site mutation. In flow-cytometric titrations on HEK-293F transfectants, platelets and HUVECs, M-204 uniquely reached only about half-maximal binding to αIIbβ3 but not αvβ3. In light transmission aggregometry, only M-204 induced platelet aggregation, peaking at 2 µg/ml and weakening at higher concentrations. Format engineering — Fab, F(ab')2, Fc-dead (PG-LALA/N297A/H435A) and bispecific duobody variants — plus FcγRIIa blockade established that aggregation requires bivalent HPA-1a engagement and intact FcγRIIa. HADDOCK docking benchmarked against new crystal structures (PDB 9YBH, 9Q68) shows distinct constant-region orientations, proposed to explain differential FcγRIIa engagement. Limitations: aggregation rests on 2-3 donors, some figures mark p<0.1 as significant, the crosslinking mechanism is inferred indirectly rather than measured, and clinical relevance remains speculative.
Review complete
Assessment at a glance
6
risk flags identified
● high 0
● medium 3
● low 3
5 strengths · 5 weaknesses · 5 author questions
AI text signal = Binoculars zero-shot detector score over 20 sampled passages (Fast-DetectGPT co-reported) — absence does not prove human authorship, and a flag does not imply misconduct.
Levels reflect verification complexity — not a quality score. Evolve never rates your paper.
Key claims under review
- M-204 is the first reported anti-HPA-1a monoclonal that directly induces platelet aggregation, and this requires both bivalent HPA-1a engagement and intact FcγRIIa binding.
- M-204 alone among the tested clones carries a Fab-region N-glycan, which does not influence its binding or aggregating function.
- M-204's half-maximal binding plateau on αIIbβ3 reflects preferential bivalent binding rather than lower affinity.
- Crystal structures (9YBH, 9Q68) and docking show M-204 and D-204 bind HPA-1a with different Fab orientations, plausibly explaining differential FcγRIIa engagement.
Strengths
Convergent format-dissection design
Fab, F(ab')2, Fc-dead (PG-LALA/N297A/H435A), bispecific duobody and NTS→DTS aglycosylated mutants each isolate one variable (bivalency, Fc, glycan); together with FcγRIIa blockade (Fig 4B) they build a logically clean case that aggregation needs bivalent HPA-1a binding plus intact FcγRIIa.
Rigorous Fab-glycan assignment by MS
nanoLC-MS of reduced Fd' subunits quantifies 27,442 Da glycosylated vs 25,340 Da aglycosylated M-204 and 25,564 Da for D-204; the engineered N72D mutation abolishing the glycoform distribution validates site assignment (Fig 1).
Multi-system, multi-reagent binding controls
Transparent benchmarking of in-silico work
Clinically grounded genotype testing
Weaknesses
Underpowered functional experiments
Nonstandard significance threshold
Mechanism asserted beyond direct evidence
Narrow comparator basis for uniqueness claim
Reproducibility infrastructure missing
Full Review Report
$1.99 · one-timeUnlock the complete preliminary analysis Evolve produced for this paper.
Report preview
Scope & Claims
This bioRxiv preprint (posted September 17, 2026; not yet peer reviewed) structurally and functionally characterizes two patient-derived monoclonal anti-HPA-1a antibodies — D-204 and M-204 — isolated from a mother with severe fetal and neonatal alloimmune thrombocytopenia (FNAIT). Central claims: (1) M-204 uniquely induces platelet aggregation; (2) aggregation requires bivalent HPA-1a engagement by both Fab arms plus intact FcγRIIa binding; (3) M-204 alone carries a Fab N-glycan that is functionally silent; (4) distinct Fab binding orientations (crystal structures PDB 9YBH and 9Q68, from companion work ref 29) explain differential FcγRIIa engagement. The evidence spans biochemistry (SDS-PAGE, nanoLC-MS), cell binding across recombinant and endogenous systems, functional aggregometry, antibody-format engineering and computational modelling.
The remaining sections cover Methodology Assessment, Statistical Evidence, Results & Reproducibility, Limitations & Risks, and Verdict & Recommendations.
- All 5 strengths & 5 weaknesses, analyzed in detail
- 6 risk flags with severity, section & reviewer questions
- Methods & statistical evidence assessment
- 5 questions a peer reviewer would ask
- Full six-dimension evaluation report & recommendations
One-time purchase · this paper only
One-time purchase, this paper only. AI-generated preliminary analysis — not peer review.
Frequently asked questions
What is FNAIT and what causes it?
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a bleeding disorder in which a pregnant mother produces antibodies against paternally inherited platelet antigens — most often HPA-1a — on the fetus's platelets. The antibodies cross the placenta, destroy fetal platelets, and can cause severe thrombocytopenia or intracranial hemorrhage.
What is new about antibody M-204 in this study?
M-204 is a monoclonal anti-HPA-1a antibody isolated from a mother with severe FNAIT. Unlike the other anti-HPA-1a monoclonals tested (D-204, B2G1, 26.4), it can directly cause platelet aggregation by binding HPA-1a with both Fab arms and engaging the platelet receptor FcγRIIa. It also uniquely carries an N-glycan on its antigen-binding Fab region, though this glycan proved functionally irrelevant.
Does this mean anti-HPA-1a antibodies cause blood clots in FNAIT babies?
Not demonstrated. The authors show platelet activation by one lab-isolated antibody and note that FcγRIIa-driven platelet activation is linked to thrombosis in other settings; they themselves state that any contribution to FNAIT severity or fetal thrombosis remains speculative until polyclonal patient antibodies with M-204-like properties are found.
Why did M-204 show only half-maximal binding to platelets in flow cytometry?
The authors propose M-204 preferentially binds HPA-1a bivalently — with both Fab arms engaged — which halves the number of antibody molecules detectable per antigen compared with monovalent binders. Supporting this, a monovalent bispecific version of M-204 regained a full binding plateau but lost the ability to aggregate platelets.
About this review
This is an AI-generated preliminary review by Evolve.Pub, produced from the openly available text of the paper. It is not peer review and does not represent the authors' views. The canonical record of the paper is at the publisher link above.
- Figures are not visible in the extracted text; quantitative judgments rely on figure legends and reported statistics only.
- Abstract is truncated mid-sentence in the source text (ends 'which is a uniq...').
- Reference numbering appears garbled in extraction (e.g., citation clusters like '47,4827'), so some citation attributions may be misread.
- Supplemental figures are available only as legends; underlying data cannot be verified from text.
Go deeper on this paper
Wrote a paper? Stress-test it before reviewers do.
Upload your manuscript for the same structured scrutiny — reasoning, statistics, evidence, figures, and reproducibility.